Compare iShares MSCI Taiwan ETF (EWT) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Taiwan ETF vs Summit Therapeutics Inc — how do they compare? iShares MSCI Taiwan ETF trades at $114.08 (market cap $12.74B), while Summit Therapeutics Inc trades at $17.45 (market cap $13.71B). The key difference: iShares MSCI Taiwan ETF and Summit Therapeutics Inc are close in size by market cap, and iShares MSCI Taiwan ETF is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Taiwan ETF for 52 Days and Summit Therapeutics Inc for 16 Days on average.
| EWT | SMMT | |
|---|---|---|
Market Cap | $12.74B | $13.71B |
Volume | 8,470,920 | 6,173,057 |
Sector | Broad Market / Factor | Health |
52-Week High | $118.00 | $26.38 |
52-Week Low | $60.03 | $12.43 |
Typical Hold Time | 52 Days | 16 Days |
Enterprise Value | — | $13.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWT trades at $114.01, down 1.92% on the day, with technical indicators showing a bullish trend supported by moving averages while oscillators remain neutral. The ETF maintains strong exposure to Taiwan's semiconductor sector, particularly TSMC, which represents 22.5% of its portfolio. Recent news highlights Taiwan's strategic importance in AI chip manufacturing and ongoing US-Taiwan economic cooperation, with Taiwanese companies planning $20 billion in US investments driven by AI demand (Reuters, 2026-09-02).
The outlook remains positive given Taiwan's central role in AI semiconductor supply chains, though geopolitical tensions with China present significant risks. Analyst sentiment is generally bullish with institutional investors increasing positions, including Bank of America's 22.4% stake increase in Q2 2026. Key support levels at $110-$112 provide downside protection while resistance sits at $115-$117.
Summit Therapeutics (SMMT) trades at $17.29, down 3.68% on the day, amid a bullish technical signal driven by moving averages. The company reported no revenue and a net loss of $1.08 billion in 2025, with negative profitability ratios, but recent news of a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations has boosted investor optimism.
The outlook is speculative, with significant upside potential based on the $29.33 analyst consensus price target, but high execution risk remains as the company is pre-revenue and reliant on clinical trial success. Key catalysts include upcoming trial results for ivonescimab, while risks involve drug development setbacks and cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Taiwan ETF
EWT tracks the MSCI Taiwan 25/50 Index, providing targeted exposure to large and mid-cap companies in Taiwan. It is heavily concentrated in the information technology sector, serving as a liquid instrument for investors seeking a single-country view of Taiwan's export-oriented and tech-driven economy.
Read more on EWT →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
